Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
OBJECTIVE
The impact of stereotactic body radiotherapy (SBRT) on 3-year progression-free survival of medically inoperable patients with stage I non-small-cell lung cancer (NSCLC) was analyzed in a prospective phase II study.


METHODS
Fifty-seven patients with T1NOMO (70%) and T2N0M0 (30%) were included between August 2003 and September 2005 at seven different centers in Sweden, Norway, and Denmark and observed up to 36 months. SBRT was delivered with 15 Gy times three at the 67% isodose of the planning target volume.


RESULTS
Progression-free survival at 3 years was 52%. Overall- and cancer-specific survival at 1, 2, and 3 years was 86%, 65%, 60%, and 93%, 88%, 88%, respectively. There was no statistically significant difference in survival between patients with T1 or T2 tumors. At a median follow-up of 35 months (range, 4 to 47 months), 27 patients (47%) were deceased, seven as a result of lung cancer and 20 as a result of concurrent disease. Kaplan-Meier estimated local control at 3 years was 92%. Local relapse was observed in four patients (7%). Regional relapse was observed in three patients (5%). Nine patients (16%) developed distant metastases. The estimated risk of all failure (local, regional, or distant metastases) was increased in patients with T2 (41%) compared with those with T1 (18%) tumors (P = .027).


CONCLUSIONS
With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.
Baumann
Pia
P
Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. pia.baumann@karolinska.se
Nyman
Jan
J
Hoyer
Morten
M
Wennberg
Berit
B
Gagliardi
Giovanna
G
Lax
Ingmar
I
Drugge
Ninni
N
Ekberg
Lars
L
Friesland
Signe
S
Johansson
Karl-Axel
KA
Lund
Jo-Asmund
JA
Morhed
Elisabeth
E
Nilsson
Kristina
K
Levin
Nina
N
Paludan
Merete
M
Sederholm
Christer
C
Traberg
Anders
A
Wittgren
Lena
L
Lewensohn
Rolf
R
D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D004417:Dyspnea / Q000209:etiology; D005221:Fatigue / Q000209:etiology; D005260:Female; D005355:Fibrosis / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010996:Pleural Effusion / Q000209:etiology; D011446:Prospective Studies; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D055752:Small Cell Lung Carcinoma / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome